Stephen Skjei, MD
Endocrinology, Diabetes & Metabolism · Holly Springs, GANPI 1518994607
Payments from drug & device makers
Across 117 payments — averaging $24.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$385
- BETA Bionics, Inc.$264
- Insulet Corporation$252
- Dexcom, Inc.$191
- Novo Nordisk$182
- Lilly USA, LLC$181
- plus $1K from 27 others
What the payments were for
- Food & beverage$2,906100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 12 | $385 |
| BETA Bionics, Inc. | 3 | $264 |
| Insulet Corporation | 4 | $252 |
| Dexcom, Inc. | 11 | $191 |
| Novo Nordisk | 9 | $182 |
| Lilly USA, LLC | 10 | $181 |
| Amgen(2 entities) | 9 | $168 |
| Cequr Corporation | 2 | $111 |
| Boehringer Ingelheim | 5 | $104 |
| Sequel Med Tech, LLC | 5 | $103 |
| Idorsia Pharmaceuticals US Inc | 5 | $88 |
| Mannkind Corporation | 4 | $82 |
| Tandem Diabetes Care, Inc. | 4 | $76 |
| AbbVie | 5 | $68 |
| Medtronic | 3 | $65 |
| Radius Health, Inc. | 2 | $60 |
| Sanofi-aventis U.S. LLC | 3 | $60 |
| Amneal Pharmaceuticals LLC | 3 | $53 |
| Bayer | 2 | $49 |
| Ascensia Diabetes Care US Inc. | 2 | $41 |
| Neurocrine Biosciences, Inc. | 1 | $33 |
| Vanda Pharmaceuticals Inc. | 1 | $33 |
| Ascendis Pharma Endocrinology Inc | 2 | $32 |
| Madrigal Pharmaceuticals | 1 | $31 |
| Harmony Biosciences LLC | 1 | $31 |
| Astellas Pharma US Inc | 1 | $29 |
| Avadel CNS Pharmaceuticals, LLC | 1 | $28 |
| Xeris Pharmaceuticals, Inc. | 1 | $21 |
| Eisai Inc. | 1 | $20 |
| Almatica Pharma LLC | 1 | $17 |
| Azurity Pharmaceuticals, Inc. | 1 | $17 |
| Zealand Pharma US, Inc. | 1 | $17 |
| Antares Pharma, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- iLet Bionic Pancreas$730
- Omnipod$186
- FreeStyle Libre 2$128
How this compares
$2,906 in reported general payments places this provider in the 45th percentile of 222 endocrinology, diabetes & metabolism providers in Georgia.
See all endocrinology, diabetes & metabolism providers in Georgia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 276 | $330,734 |
| JardianceEmpagliflozin | 263 | $283,991 |
| OzempicSemaglutide | 195 | $281,164 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 130 | $144,790 |
| TrulicityDulaglutide | 70 | $116,025 |
| JanuviaSitagliptin Phosphate | 65 | $76,100 |
| ForteoTeriparatide | 18 | $75,368 |
| Tresiba Flextouch U-100Insulin Degludec | 76 | $64,144 |
| FarxigaDapagliflozin Propanediol | 54 | $61,671 |
| OmnitropeSomatropin | 13 | $47,467 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 23 | $45,400 |
| Xultophy 100-3.6Insulin Degludec/Liraglutide | 32 | $44,980 |
| ProliaDenosumab | 22 | $37,908 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 16 | $34,410 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 47 | $33,199 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Forteo, Humalog | $181 | $530,766377 claims |
| Novo NordiskOzempic, Xultophy 100-3.6, Rybelsus, Novolog | $182 | $349,698264 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Tradjenta | $104 | $318,099296 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus | $60 | $150,021174 claims |
| AmgenProlia | $168 | $37,90822 claims |
| AbbVieSynthroid | $68 | $14,559142 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $53 | $4,375466 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 222 endocrinology, diabetes & metabolism providers in Georgia.
Other endocrinology, diabetes & metabolism in Holly Springs
- Bruce BodeAtlanta$18.3M
- Gulliermo UmpierrezAtlanta$6.6M
- John ReedRoswell$5.7M
- Thomas JonesMacon$4.8M
- Steven LeichterColumbus$3.1M
- Jason BernerJasper$2.6M
- Ashwini GoreMacon$2.6M
- Adeniyi OdugbesanLawrenceville$1.8M
- David RobertsonAtlanta$1.7M
- Thomas ZieglerAtlanta$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.